Detail akcie Bicara Therap Rg online

Business Summary: Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Bicara Therapeutics Inc revenues was not reported. Net loss increased from $47M to $100.6M. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase from $55.8M to $114.5M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.89 to -$1.84.